Table 2. Evidence of bioactivity of human anti-PR3 IgG on primed human neutrophils in vitro.

Stimulus	Superoxide release (AUC)	Degranulation (OD at 450 nm)	Creatinine (mg/dL)	Organs involved	BVAS
Anti-PR3-1 IgG	1236±122	0.35±0.06	1.3	K,L,S,N	26
Anti-PR3-2 IgG	1003±79	0.57±0.1	2.1	K,L	18
Anti-PR3-3 IgG	1180±120	0.13±0.03	9.1	K,L	20
Disease control IgG	291±40	0.12± 0.03	1.5		N/A
Healthy control IgG	161±16	0.13±0.02			N/A
fMLP	1378±153	1.06±0.10			N/A

IgG samples were incubated with primed human PMNs and superoxide release and degranulation were measured. Each assay was repeated at least 9 times using a minimum of 4 separate PMN donors. Organs involved: K = kidney, L = lung, S = skin, N = Nasal and sinus. Values represent mean±SEM.